Comments
Loading...

Avidity Biosciences Analyst Ratings

RNANASDAQ
Logo brought to you by Benzinga Data
$32.14
At close: Jun 12 EDT
$32.14
0.000.00%
Pre-Market: 4:24 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$96.00
Lowest Price Target1
$20.00
Consensus Price Target1
$62.33

Avidity Biosciences Analyst Ratings and Price Targets | NASDAQ:RNA | Benzinga

Avidity Biosciences Inc has a consensus price target of $62.33 based on the ratings of 18 analysts. The high is $96 issued by Cantor Fitzgerald on September 18, 2024. The low is $20 issued by Evercore ISI Group on March 31, 2023. The 3 most-recent analyst ratings were released by Raymond James, Citigroup, and Barclays on June 11, 2025, June 10, 2025, and June 10, 2025, respectively. With an average price target of $66.33 between Raymond James, Citigroup, and Barclays, there's an implied 106.39% upside for Avidity Biosciences Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Feb
7
Mar
1
Apr
3
May
5
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Raymond James
Citigroup
Barclays
B of A Securities
Chardan Capital

1calculated from analyst ratings

Analyst Ratings for Avidity Biosciences

Buy NowGet Alert
06/11/2025Buy Now102.24%Raymond James
Michael Freeman21%
→ $65Initiates → Strong BuyGet Alert
06/10/2025Buy Now133.35%Citigroup
Geoff Meacham63%
$70 → $75MaintainsBuyGet Alert
06/10/2025Buy Now83.57%Barclays
Gena Wang52%
$57 → $59MaintainsOverweightGet Alert
06/09/2025Buy Now68.01%B of A Securities
Geoff Meacham63%
$48 → $54MaintainsBuyGet Alert
06/09/2025Buy Now133.35%Chardan Capital
Keay Nakae57%
$65 → $75MaintainsBuyGet Alert
05/12/2025Buy Now111.57%HC Wainwright & Co.
Andrew Fein63%
$72 → $68MaintainsBuyGet Alert
05/09/2025Buy Now102.24%Chardan Capital
Keay Nakae57%
$65 → $65MaintainsBuyGet Alert
05/07/2025Buy Now102.24%Chardan Capital
Keay Nakae57%
$65 → $65MaintainsBuyGet Alert
04/09/2025Buy Now86.68%Needham
Joseph Stringer61%
$60 → $60ReiteratesBuy → BuyGet Alert
03/18/2025Buy Now124.02%HC Wainwright & Co.
Andrew Fein63%
$72 → $72ReiteratesBuy → BuyGet Alert
03/17/2025Buy Now86.68%Needham
Joseph Stringer61%
$60 → $60ReiteratesBuy → BuyGet Alert
03/17/2025Buy Now124.02%HC Wainwright & Co.
Andrew Fein63%
$72 → $72ReiteratesBuy → BuyGet Alert
03/17/2025Buy Now102.24%Chardan Capital
Keay Nakae57%
$65 → $65MaintainsBuyGet Alert
03/13/2025Buy Now117.8%Citigroup
Geoff Meacham63%
→ $70Initiates → BuyGet Alert
03/12/2025Buy Now124.02%BMO Capital
Kostas Biliouris35%
→ $72Initiates → OutperformGet Alert
03/10/2025Buy Now49.35%B of A Securities
Geoff Meacham63%
$51 → $48MaintainsBuyGet Alert
03/07/2025Buy Now117.8%Scotiabank
Louise Chen57%
→ $70Initiates → Sector OutperformGet Alert
02/28/2025Buy Now77.35%Barclays
Gena Wang52%
$63 → $57MaintainsOverweightGet Alert
02/28/2025Buy Now102.24%Chardan Capital
Keay Nakae57%
$65 → $65MaintainsBuyGet Alert
01/21/2025Buy Now108.46%RBC Capital
Luca Issi45%
$67 → $67ReiteratesOutperform → OutperformGet Alert
01/10/2025Buy Now124.02%HC Wainwright & Co.
Andrew Fein63%
$72 → $72ReiteratesBuy → BuyGet Alert
12/20/2024Buy Now124.02%HC Wainwright & Co.
Andrew Fein63%
→ $72Initiates → BuyGet Alert
11/26/2024Buy Now108.46%RBC Capital
Luca Issi45%
→ $67Initiates → OutperformGet Alert
11/13/2024Buy Now102.24%Chardan Capital
Keay Nakae57%
$65 → $65MaintainsBuyGet Alert
11/13/2024Buy Now86.68%Needham
Joseph Stringer61%
$60 → $60ReiteratesBuy → BuyGet Alert
10/31/2024Buy Now86.68%Needham
Joseph Stringer61%
$60 → $60ReiteratesBuy → BuyGet Alert
10/30/2024Buy Now102.24%Chardan Capital
Keay Nakae57%
$60 → $65MaintainsBuyGet Alert
10/21/2024Buy Now142.69%TD Cowen
Ritu Baral39%
$56 → $78MaintainsBuyGet Alert
09/24/2024Buy Now83.57%Goldman Sachs
Corinne Johnson23%
→ $59Initiates → BuyGet Alert
09/18/2024Buy Now198.69%Cantor Fitzgerald
Eric Schmidt35%
$96 → $96ReiteratesOverweight → OverweightGet Alert
09/16/2024Buy Now198.69%Cantor Fitzgerald
Eric Schmidt35%
$96 → $96ReiteratesOverweight → OverweightGet Alert
09/09/2024Buy Now198.69%Cantor Fitzgerald
Eric Schmidt35%
$96 → $96ReiteratesOverweight → OverweightGet Alert
08/28/2024Buy Now96.02%Barclays
Gena Wang52%
→ $63Initiates → OverweightGet Alert
08/26/2024Buy Now64.9%Evercore ISI Group
Josh Schimmer56%
$54 → $53MaintainsOutperformGet Alert
08/13/2024Buy Now86.68%Needham
Joseph Stringer61%
$60 → $60ReiteratesBuy → BuyGet Alert
08/12/2024Buy Now68.01%Evercore ISI Group
Josh Schimmer56%
$45 → $54MaintainsOutperformGet Alert
08/09/2024Buy Now86.68%Chardan Capital
Keay Nakae57%
$45 → $60MaintainsBuyGet Alert
06/13/2024Buy Now40.01%B of A Securities
Geoff Meacham63%
$40 → $45MaintainsBuyGet Alert
06/12/2024Buy Now43.12%Needham
Joseph Stringer61%
$35 → $46MaintainsBuyGet Alert
06/12/2024Buy Now40.01%Chardan Capital
Keay Nakae57%
$33 → $45MaintainsBuyGet Alert
06/12/2024Buy Now40.01%Evercore ISI Group
Josh Schimmer56%
$40 → $45MaintainsOutperformGet Alert
06/10/2024Buy Now8.9%Needham
Joseph Stringer61%
$35 → $35ReiteratesBuy → BuyGet Alert
05/10/2024Buy Now8.9%Needham
Joseph Stringer61%
$35 → $35ReiteratesBuy → BuyGet Alert
05/10/2024Buy Now2.68%Chardan Capital
Keay Nakae57%
$33 → $33MaintainsBuyGet Alert
05/03/2024Buy Now24.46%B of A Securities
Geoff Meacham63%
→ $40Initiates → BuyGet Alert
04/11/2024Buy Now8.9%Needham
Joseph Stringer61%
$35 → $35ReiteratesBuy → BuyGet Alert
03/14/2024Buy Now86.68%Cantor Fitzgerald
Eric Schmidt35%
→ $60Initiates → OverweightGet Alert
03/05/2024Buy Now2.68%Chardan Capital
Keay Nakae57%
$23 → $33MaintainsBuyGet Alert
03/04/2024Buy Now8.9%Needham
Joseph Stringer61%
$35 → $35ReiteratesBuy → BuyGet Alert
02/29/2024Buy Now8.9%Needham
Joseph Stringer61%
$35 → $35ReiteratesBuy → BuyGet Alert
02/29/2024Buy Now-28.44%Chardan Capital
Keay Nakae57%
→ $23ReiteratesBuy → BuyGet Alert
01/03/2024Buy Now55.57%Wells Fargo
Yanan Zhu45%
$50 → $50ReiteratesOverweight → OverweightGet Alert
11/29/2023Buy Now8.9%Needham
Joseph Stringer61%
→ $35ReiteratesBuy → BuyGet Alert
08/09/2023Buy Now-6.66%Credit Suisse
Judah Frommer64%
→ $30ReiteratesOutperform → OutperformGet Alert
08/09/2023Buy Now-28.44%Chardan Capital
Keay Nakae57%
$27 → $23MaintainsBuyGet Alert
08/09/2023Buy Now8.9%Needham
Joseph Stringer61%
→ $35ReiteratesBuy → BuyGet Alert
05/22/2023Buy Now-37.77%Evercore ISI Group
Josh Schimmer56%
→ $20UpgradeIn-Line → OutperformGet Alert
05/17/2023Buy Now8.9%Needham
Joseph Stringer61%
→ $35ReiteratesBuy → BuyGet Alert
05/11/2023Buy Now55.57%Wells Fargo
Yanan Zhu45%
$55 → $50MaintainsOverweightGet Alert
05/10/2023Buy Now-6.66%Credit Suisse
Judah Frommer64%
→ $30Reiterates → OutperformGet Alert
04/28/2023Buy Now8.9%Needham
Joseph Stringer61%
→ $35Reiterates → BuyGet Alert
03/31/2023Buy Now-6.66%Credit Suisse
Judah Frommer64%
$35 → $30MaintainsOutperformGet Alert
03/31/2023Buy Now-37.77%Evercore ISI Group
Joshua Schimmer45%
→ $20DowngradeOutperform → In-LineGet Alert
03/31/2023Buy Now-15.99%Chardan Capital
Keay Nakae57%
→ $27Reiterates → BuyGet Alert
03/01/2023Buy Now8.9%Credit Suisse
Judah Frommer64%
→ $35Reiterates → OutperformGet Alert
03/01/2023Buy Now-15.99%Chardan Capital
Keay Nakae57%
→ $27Reiterates → BuyGet Alert
03/01/2023Buy Now8.9%Needham
Joseph Stringer61%
→ $35Reiterates → BuyGet Alert
01/04/2023Buy Now71.13%Wells Fargo
Yanan Zhu45%
$60 → $55MaintainsOverweightGet Alert
12/15/2022Buy Now8.9%Credit Suisse
Judah Frommer64%
$33 → $35MaintainsOutperformGet Alert
12/15/2022Buy Now120.91%Raymond James
Steven Seedhouse58%
$30 → $71MaintainsStrong BuyGet Alert
12/14/2022Buy Now120.91%Raymond James
Steven Seedhouse58%
$30 → $71MaintainsStrong BuyGet Alert
11/09/2022Buy Now2.68%Credit Suisse
Judah Frommer64%
$32 → $33MaintainsOutperformGet Alert
11/09/2022Buy Now-6.66%Raymond James
Steven Seedhouse58%
$29 → $30MaintainsStrong BuyGet Alert
09/27/2022Buy Now8.9%Needham
Joseph Stringer61%
$50 → $35MaintainsBuyGet Alert
09/27/2022Buy Now-15.99%Chardan Capital
Keay Nakae57%
$29 → $27MaintainsBuyGet Alert
07/20/2022Buy Now-9.77%Chardan Capital
Keay Nakae57%
→ $29Initiates → BuyGet Alert
07/12/2022Buy Now-9.77%Raymond James
Steven Seedhouse58%
→ $29Initiates → Strong BuyGet Alert

FAQ

Q

What is the target price for Avidity Biosciences (RNA) stock?

A

The latest price target for Avidity Biosciences (NASDAQ:RNA) was reported by Raymond James on June 11, 2025. The analyst firm set a price target for $65.00 expecting RNA to rise to within 12 months (a possible 102.24% upside). 37 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Avidity Biosciences (RNA)?

A

The latest analyst rating for Avidity Biosciences (NASDAQ:RNA) was provided by Raymond James, and Avidity Biosciences initiated their strong buy rating.

Q

When was the last upgrade for Avidity Biosciences (RNA)?

A

The last upgrade for Avidity Biosciences Inc happened on May 22, 2023 when Evercore ISI Group raised their price target to $20. Evercore ISI Group previously had an in-line for Avidity Biosciences Inc.

Q

When was the last downgrade for Avidity Biosciences (RNA)?

A

The last downgrade for Avidity Biosciences Inc happened on March 31, 2023 when Evercore ISI Group changed their price target from N/A to $20 for Avidity Biosciences Inc.

Q

When is the next analyst rating going to be posted or updated for Avidity Biosciences (RNA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avidity Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avidity Biosciences was filed on June 11, 2025 so you should expect the next rating to be made available sometime around June 11, 2026.

Q

Is the Analyst Rating Avidity Biosciences (RNA) correct?

A

While ratings are subjective and will change, the latest Avidity Biosciences (RNA) rating was a initiated with a price target of $0.00 to $65.00. The current price Avidity Biosciences (RNA) is trading at is $32.14, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch